About Albert Bourla
Albert Bourla, chairman and CEO of Pfizer, said on the company’s first-quarter 2026 earnings call that the company’s strong performance reflected “disciplined execution” and that new and acquired products grew 22% in the quarter. He stated that Pfizer does not plan a large merger in the near term, describing the next few years as a time to “execute on AI transformation” rather than pursue a mega-merger. Bourla also highlighted recent patent settlements for Vyndamax, which he said give the company confidence it will enter a period of high single-digit revenue growth starting in 2029. He noted that Pfizer invested nearly $80 billion in recent years to acquire molecules and pipelines to offset upcoming patent losses.
In multiple interviews, Bourla discussed the rise of China’s pharmaceutical sector, arguing that the U.S. should focus on improving its own innovation rather than trying to slow China’s progress. He described China’s scientific capabilities as having a “meteoric rise” and said that by the end of the decade, eight of the world’s top ten universities based on peer-reviewed publications were Chinese. Bourla expressed optimism about artificial intelligence, calling it “transformative” and predicting it will contribute to a “scientific renaissance” in medicine. He also commented on U.S. health policy, saying he was encouraged by recent statements from Trump administration officials about modernizing the FDA and accelerating drug development, though he said he had not yet seen practical effects. Bourla described his increased time in Washington as necessary because health care has become “extremely politicized” and because governments are major customers for Pfizer.
Source: AI-verified profile updated from Albert Bourla's recent appearances.
Browse all interviews →
✨ AI-enhanced transcript with speaker attribution
I
Interviewer0:00
A huge price tag, tell us why Seagen is worth it for Pfizer.
A
Albert Bourla0:21
Okay Mike, very nice to see you. But cancer is one of the biggest therapeutic areas, and right now, one in three people in the world are going to have cancer in their lifetime. Unfortunately, the numbers that people are affected is even larger because people are if not there's patients that will be affected as a husband or wife, they will be affected as a daughter or son, and even worse their father and mother and see them is having one of the greatest technologies to battle cancer. It's called ADCs; these are turbo-charged guided missiles attacking the cancer cells and can make a huge difference. I would say this is something like the mRNA for vaccines; it is for cancer. So we think that we can make a very big difference with this technology in our hands and provide a relief to the world at a scale that has not been seen before from this devastating disease.
I
Interviewer1:23
Wow, and you also expect that this could contribute something like 10 billion dollars in revenue for Pfizer by 2030, contributing to an overall goal you've set that you've been trying to meet through M&A. Just tell us about, you know, what the financial impact on Pfizer will be here.
A
Albert Bourla1:42
It's going to be very positive, the financial impact on Pfizer. We should be able to fill the gap, as you said, of between 25 and 30. This is where our facing alloys and to get the target to achieve 25 billions in M&A. Until yesterday, we had 10 of these billions in the bucket, and now we have another 10, more or less. So we are 80% in this goal, and that gives certain clarity to investors that our situation in the years 25 to 30 is pretty good. On the other hand, also these are very specific things about this acquisition; we can add value to what Seagen is bringing. It's more or less the same situation when another technology like mRNA was in our hands, with our scale, with our capabilities. This is the same here: we can achieve tremendous revenue synergies and cost synergies by being able to implement things at scale. The financial returns, I believe, will be very good with a relatively very low risk profile.
